Dad et al, AJKD, "Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial"

Table S1. Baseline data from the entire eligible cohort and following propensity score matching for all variables used in the propensity score.

	Non-Matched					*Propensity Matched (0.1 Caliper)*			
	Total (N = 3122)	**No Aspirin (N=1998)**	**Aspirin (N=1124)**	*p-value*	*Std diff*	**Total (N=1962)**	**No Aspirin (N =981%)**	**Aspirin (N=981)**	*Std diff*
Age (years)	50.8 ± 9.3	49.7 ± 9.1	52.9 ± 9.3	<0.001	-34.8%	52.2 ± 9.2	52.2 ± 9.4	52.2 ± 9.2	-0.2%
Female	1242 (39.8%)	812 (40.6%)	430 (38.3%)	0.19	4.9%	769 (39.2%)	385 (39.3%)	384 (39.1%)	0.2%
Race									
White	2333 (74.7%)	1441 (72.1%)	892 (79.4%)		-16.9%	1505 (76.7%)	748 (76.3%)	757 (77.2%)	-2.2%
Black	576 (18.5%)	404 (20.2%)	172 (15.3%)	<0.001	12.9%	338 (17.2%)	173 (17.6%)	165 (16.8%)	2.2%
Other	213 (6.8%)	153 (7.7%)	60 (5.3%)		9.4%	119 (6.1%)	60 (6.1%)	59 (6.0%)	0.4%
Country									
United States	2204 (70.6%)	1374 (68.8%)	830 (73.8%)	<0.001	-11.2%	1413 (72.0%)	701 (71.5%)	712 (72.6%)	-2.5%
Canada	405 (13.0%)	304 (15.2%)	101 (9.0%)		19.2%	186 (9.5%)	90 (9.2%)	96 (9.8%)	-2.1%
Brazil	513 (16.4%)	320 (16.0%)	193 (17.2%)		-3.1%	363 (18.5%)	190 (19.4%)	173 (17.6%)	4.5%
Treatment Group Assignment									
Low dose vitamin	1560 (50.0%)	979 (49.0%)	581 (51.7%)	0.2	-5.4%	1012 (51.6%)	511 (52.1%)	501 (51.1%)	2.0%
High dose vitamin	1562 (50.0%)	1019 (51.0%)	543 (48.3%)		5.4%	950 (48.4%)	470 (47.9%)	480 (48.9%)	-2.0%
Diabetes	1101 (35.3%)	578 (28.9%)	523 (46.5%)	<0.001	-36.9%	820 (41.8%)	407 (41.5%)	413 (42.1%)	-1.2%
Diabetes Medication Use									

Dad et al, AJKD, "Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial"

Thiazolidinedione	96 (3.1%)	49 (2.5%)	47 (4.2%)	0.01	-9.7%	74 (3.8%)	36 (3.7%)	38 (3.9%)	-1.1%
Acarbose	4 (0.1%)	2 (0.1%)	2 (0.2%)	0.6	-2.1%	3 (0.2%)	1 (0.1%)	2 (0.2%)	-2.6%
Metformin	53 (1.7%)	31 (1.6%)	22 (2.0%)	0.4	-3.1%	40 (2.0%)	21 (2.1%)	19 (1.9%)	1.4%
Insulin	560 (17.9%)	282 (14.1%)	278 (24.7%)	<0.001	-27.1%	416 (21.2%)	211 (21.5%)	205 (20.9%)	1.5%
Sulfonylurea	216 (6.9%)	132 (6.6%)	84 (7.5%)	0.4	-3.4%	147 (7.5%)	69 (7.0%)	78 (8.0%)	-3.5%
Hypertension	2845 (91.1%)	1793 (89.7%)	1052 (93.6%)	<0.001	-14.0%	1826 (93.1%)	914 (93.2%)	912 (93.0%)	0.8%
Antihypertensive Medication Use	2600 (83.3%)	1635 (81.8%)	965 (85.9%)	0.004	-10.9%	1664 (84.8%)	829 (84.5%)	835 (85.1%)	-1.7%
ACE inhibitor and/or ARB	1349 (43.2%)	832 (41.6%)	517 (46.0%)	0.02	-8.8%	893 (45.5%)	447 (45.6%)	446 (45.5%)	0.2%
ACE inhibitor	989 (31.7%)	605 (30.3%)	384 (34.2%)	0.03	-8.3%	663 (33.8%)	337 (34.4%)	326 (33.2%)	2.4%
Angiotensin Receptor Blocker	408 (13.1%)	257 (12.9%)	151 (13.4%)	0.65	-1.7%	256 (13.1%)	122 (12.4%)	134 (13.7%)	-3.6%
Beta Blocker	1650 (52.9%)	1006 (50.4%)	644 (57.3%)	<0.001	-14.0%	1105 (56.3%)	558 (56.9%)	547 (55.8%)	2.3%
Loop Diuretics	861 (27.6%)	502 (25.1%)	359 (31.9%)	<0.001	-15.1%	590 (30.1%)	295 (30.1%)	295 (30.1%)	0.0%
Other Diuretics	311 (10.0%)	205 (10.3%)	106 (9.4%)	0.5	2.8%	187 (9.5%)	93 (9.5%)	94 (9.6%)	-0.3%
Smoking status									
Never	1629 (52.2%)	1056 (52.9%)	573 (51.0%)	0.2	3.8%	1002 (51.1%)	499 (50.9%)	503 (51.3%)	-0.8%
Current	351 (11.2%)	234 (11.7%)	117 (10.4%)		4.2%	201 (10.2%)	98 (10.0%)	103 (10.5%)	-1.7%
Ever	1142 (36.6%)	708 (35.4%)	434 (38.6%)		-6.6%	759 (38.7%)	384 (39.1%)	375 (38.2%)	1.9%
Living donor	1352 (43.3%)	871 (43.6%)	481 (42.8%)	0.7	1.6%	862 (43.9%)	438 (44.7%)	424 (43.2%)	2.9%
Immunosuppression									

Dad et al, AJKD, "Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial"

Medication									
CNI-based regimen	2769 (88.7%)	1757 (87.9%)	1012 (90.0%)	0.08	-6.7%	1761 (89.8%)	885 (90.2%)	876 (89.3%)	3.0%
Cyclosporine	1603 (51.4%)	1016 (50.9%)	587 (52.2%)	0.5	-2.7%	1032 (52.6%)	526 (53.6%)	506 (51.6%)	4.1%
Tacrolimus	1173 (37.6%)	744 (37.2%)	429 (38.2%)	0.6	-1.9%	735 (37.5%)	361 (36.8%)	374 (38.1%)	-2.7%
Sirolimus	262 (8.4%)	154 (7.7%)	108 (9.6%)	0.07	-6.8%	175 (8.9%)	89 (9.1%)	86 (8.8%)	1.1%
Mycophenolate	2018 (64.6%)	1276 (63.9%)	742 (66.0%)	0.2	-4.5%	1295 (66.0%)	650 (66.3%)	645 (65.8%)	1.1%
Azathioprine	589 (18.9%)	397 (19.9%)	192 (17.1%)	0.06	7.2%	359 (18.3%)	181 (18.5%)	178 (18.1%)	0.8%
Prednisone	2853 (91.4%)	1833 (91.7%)	1020 (90.8%)	0.3	3.5%	1798 (91.6%)	904 (92.2%)	894 (91.1%)	3.7%
Cholesterol Lowering Medication									
Statin Use	1546 (49.5%)	923 (46.2%)	623 (55.4%)	<0.001	-18.5%	1043 (53.2%)	524 (53.4%)	519 (52.9%)	1.0%
Fibrate Use	90 (2.9%)	53 (2.7%)	37 (3.3%)	0.3	-3.8%	62 (3.2%)	31 (3.2%)	31 (3.2%)	0.0%
Ezetimibe Use	82 (2.6%)	50 (2.5%)	32 (2.9%)	0.6	-2.1%	53 (2.7%)	24 (2.5%)	29 (3.0%)	-3.1%
Graft vintage (years)	4.1 (1.7 – 7.5)	4.4 (1.9 – 8.2)	3.3 (1.4 – 6.7)	<0.001	22.1%	3.6 (1.6 – 6.8)	3.8 (1.7 – 6.6)	3.5 (1.5 – 6.9)	-1.6%
BMI (kg/m^2)	29.1 ± 6.4	28.9 ± 6.4	29.3 ± 6.3	0.2	-5.2%	29.1 ± 6.3	29.1 ± 6.2	29.1 ± 6.3	-1.0%
Weight (kg)	84.1 ± 20.3	83.6 ± 20.6	85.0 ± 19.9	0.07	-6.8%	84.3 ± 19.9	84.2 ± 20.2	84.3 ± 19.6	-0.5%
Systolic BP (mmHg)	135.5 ± 19.4	135.3 ± 19.0	136.0 ± 20.0	0.3	-3.6%	136.0 ± 19.5	135.9 ± 19.1	136.2 ± 20.0	-1.4%
Diastolic BP (mmHg)	79.3 ± 11.9	80.1 ± 11.8	77.8 ± 11.9	<0.001	19.0%	78.7 ± 12.0	78.7 ± 12.1	78.7 ± 11.9	0.1%
Other Medications									

Contraceptives	30 (1.0%)	17 (0.9%)	13 (1.2%)	0.4	-3.1%	19 (1.0%)	10 (1.0%)	9 (0.9%)	1.0%
Estrogen Replacement	111 (3.6%)	80 (4.0%)	31 (2.8%)	0.07	6.9%	56 (2.9%)	28 (2.9%)	28 (2.9%)	0.0%
Levothyroxine	5 (0.2%)	2 (0.1%)	3 (0.3%)	0.3	-3.9%	4 (0.2%)	2 (0.2%)	2 (0.2%)	0.0%
Raloxifene	10 (0.3%)	5 (0.3%)	5 (0.4%)	0.4	-3.3%	6 (0.3%)	3 (0.3%)	3 (0.3%)	0.0%
Tamoxifen	6 (0.2%)	1 (0.1%)	5 (0.4%)	0.02	-8.0%	1 (0.1%)	1 (0.1%)	0 (0.0%)	4.5%
Probucol	4 (0.1%)	3 (0.2%)	1 (0.1%)	0.7	1.8%	1 (0.1%)	0 (0.0%)	1 (0.1%)	-4.5%
Serum Creatinine (mg/dL)	1.7 ± 0.6	1.7 ± 0.6	1.6 ± 0.5	0.002	11.7%	1.6 ± 0.5	1.6 ± 0.5	1.6 ± 0.5	1.4%
eGFR CKD-EPI (ml/min/1.73m^2)	49.6 ± 18.0	49.2 ± 17.9	50.3 ± 18.1	0.1	-5.8%	50.0 ± 18.0	49.8 ± 17.8	50.3 ± 18.2	-3.0%
eGFR categories									
>=90	97 (3.1%)	62 (3.1%)	35 (3.1%)	0.6	-0.1%	69 (3.5%)	36 (3.7%)	33 (3.4%)	1.7%
60-90	661 (21.2%)	411 (20.6%)	250 (22.2%)		-4.1%	411 (21.0%)	192 (19.6%)	219 (22.3%)	-6.8%
45-60	967 (31.0%)	613 (30.7%)	354 (31.5%)		-1.8%	632 (32.2%)	327 (33.3%)	305 (31.1%)	4.8%
30-45	1024 (32.8%)	662 (33.1%)	362 (32.2%)		2.0%	631 (32.2%)	316 (32.2%)	315 (32.1%)	0.2%
<30	373 (12.0%)	250 (12.5%)	123 (10.9%)		4.9%	219 (11.2%)	110 (11.2%)	109 (11.1%)	0.3%
ACR (mg/g)	24.7 (8.4 – 95.6)	27.7 (8.9 – 113.8)	19.7 (7.8 – 64.3)	0.01	9.9%	22.1 (7.8 – 78.5)	23.5 (7.7 – 82.7)	21.2 (7.9 – 69.4)	6.1%
ACR categories									
<10	915 (29.3%)	559 (28.0%)	356 (31.7%)	<0.001	-8.1%	607 (30.9%)	302 (30.8%)	305 (31.1%)	-0.7%
10-29	804 (25.8%)	485 (24.3%)	319 (28.4%)		-9.3%	513 (26.2%)	245 (25.0%)	268 (27.3%)	-5.3%
30-299	1017 (32.6%)	679 (34.0%)	338 (30.1%)		8.4%	632 (32.2%)	325 (33.1%)	307 (31.3%)	3.9%

Dad et al, AJKD, "Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial"

>=300	386 (12.4%)	275 (13.8%)	111 (9.9%)		12.1%	210 (10.7%)	109 (11.1%)	101 (10.3%)	2.6%
Lipids									
Total Cholesterol (mg/dL)	186.5 ± 43.1	189.0 ± 43.2	182.3 ± 42.7	<0.001	15.6%	184.3 ± 41.8	184.8 ± 40.3	183.9 ± 43.2	2.1%
HDL Cholesterol (mg/dL)	47.0 ± 14.2	47.2 ± 14.4	46.5 ± 13.9	0.2	5.2%	46.7 ± 14.0	46.6 ± 13.9	46.9 ± 14.1	-2.2%
LDL Cholesterol (mg/dL)	102.4 ± 33.5	104.0 ± 34.0	99.6 ± 32.2	<0.001	13.3%	101.0 ± 33.1	101.2 ± 33.3	100.8 ± 32.9	1.2%
Triglycerides (mg/dL)	163 (111 – 235)	166 (113 – 236)	159 (109 – 230)	0.08	7.0%	163 (109 – 234)	166 (110 – 235)	160 (109 – 230)	2.1%
Other Labs									
Glucose (mg/dL)	113.3 ± 53.0	111.1 ± 49.5	117.3 ± 58.5	0.002	-11.5%	115.5 ± 55.9	115.6 ± 54.4	115.3 ± 57.3	0.5%
Uric acid (mg/dL)	7.7 ± 2.1	7.7 ± 2.2	7.7 ± 2.1	0.3	3.8%	7.7 ± 2.1	7.7 ± 2.1	7.6 ± 2.1	1.9%
Phosphorous (mg/dL)	3.1 ± 0.8	3.1 ± 0.8	3.1 ± 0.7	0.4	3.4%	3.1 ± 0.8	3.1 ± 0.9	3.1 ± 0.7	3.8%
Calcium (mg/dL)	9.6 ± 1.0	9.6 ± 1.0	9.7 ± 0.9	0.2	-4.8%	9.7 ± 1.0	9.7 ± 0.9	9.7 ± 1.0	1.7%
Albumin (g/dL)	4.2 ± 0.4	4.3 ± 0.4	4.2 ± 0.4	0.04	7.7%	4.2 ± 0.4	4.2 ± 0.4	4.2 ± 0.4	2.9%
Bilirubin (mg/dL)	0.6 (0.4 – 0.7)	0.5 (0.4 – 0.7)	0.6 (0.4 – 0.7)	0.7	-1.2%	0.6 (0.4 – 0.7)	0.6 (0.4 – 0.7)	0.6 (0.4 – 0.7)	-2.4%
Alkaline Phosphatase (U/L)	71.5 ± 36.4	70.9 ± 35.0	72.6 ± 38.7	0.2	-4.4%	72.0 ± 37.0	71.7 ± 34.3	72.2 ± 39.5	-1.4%
Homocysteine (umol/L)	16.4 ± 6.4	16.4 ± 6.2	16.4 ± 6.8	0.9	0.5%	16.4 ± 6.8	16.4 ± 6.6	16.4 ± 7.0	0.3%

Std diff, standardized difference; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; ACR, urine albumin to creatinine ratio; ARB, angiotensin receptor blocker; BP, blood pressure; BMI, body mass index